Synageva BioPharma (GEVA) Reports Encouraging Data from Sebelipase Alfa on LAL Deficiency
Tweet Send to a Friend
Synageva BioPharma Corp. (Nasdaq: GEVA) announced six month results from an ongoing extension study of sebelipase alfa in adults with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
